Kymera Therapeutics, Inc.

KYMR

$64.10

Name : Kymera Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $4,611,932,160.00

EPSttm : -3.6

Kymera Therapeutics, Inc.

$64.10

1.29%

$0.84

Float Short %

13.52

Margin Of Safety %

Put/Call OI Ratio

0.99

EPS Next Q Diff

-0.06

EPS Last/This Y

-0.5

EPS This/Next Y

-0.39

Price

64.05

Target Price

76.14

Analyst Recom

1.04

Performance Q

50.58

Relative Volume

0.55

Beta

2.28

Ticker: KYMR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	KYMR	60.5	0.48	0.02	2630
2025-10-21	KYMR	58.35	0.47	7.75	2676
2025-10-22	KYMR	55.77	0.48	0.04	2708
2025-10-23	KYMR	57.75	0.49	0.03	2705
2025-10-24	KYMR	58.53	0.48	0.20	2741
2025-10-27	KYMR	60.88	0.48	0.03	2745
2025-10-28	KYMR	61.99	0.47	999.99	2777
2025-10-29	KYMR	60.12	0.47	999.99	2777
2025-10-30	KYMR	61.46	0.47	999.99	2778
2025-10-31	KYMR	61.87	0.47	0.04	2777
2025-11-03	KYMR	59.69	0.46	0.10	2816
2025-11-04	KYMR	59.99	0.46	999.99	2810
2025-11-05	KYMR	59.91	0.46	0.01	2812
2025-11-06	KYMR	61	0.44	4.75	2904
2025-11-07	KYMR	58.79	0.44	0.00	2905
2025-11-10	KYMR	61.27	0.44	0.00	2913
2025-11-11	KYMR	63.42	0.48	0.00	2759
2025-11-12	KYMR	63.58	0.47	0.05	2792
2025-11-13	KYMR	63.57	0.47	53.64	2810
2025-11-14	KYMR	64.95	0.86	1.75	3562
2025-11-17	KYMR	64.09	0.99	2.00	4461
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	KYMR	60.50	5.0	-45.4	-3.41
2025-10-21	KYMR	58.31	4.8	-28.1	-3.41
2025-10-22	KYMR	55.80	4.0	-25.4	-3.42
2025-10-23	KYMR	57.78	4.0	-54.5	-3.42
2025-10-24	KYMR	58.56	4.0	-46.4	-3.42
2025-10-27	KYMR	60.88	4.0	-55.8	-3.42
2025-10-28	KYMR	61.95	4.0	-47.9	-3.42
2025-10-29	KYMR	60.08	4.0	-30.3	-3.42
2025-10-30	KYMR	61.44	4.0	-49.4	-3.42
2025-10-31	KYMR	61.84	4.0	-43.7	-3.42
2025-11-03	KYMR	59.66	4.1	-28.5	-3.42
2025-11-04	KYMR	60.03	4.1	-43.2	-3.42
2025-11-05	KYMR	59.81	4.1	-40.7	-3.42
2025-11-06	KYMR	60.99	4.1	-28.2	-3.42
2025-11-07	KYMR	58.66	3.5	-8.2	-3.52
2025-11-10	KYMR	61.26	3.5	-36.2	-3.52
2025-11-11	KYMR	63.37	5.0	-33.7	-3.49
2025-11-12	KYMR	63.55	5.0	-22.4	-3.49
2025-11-13	KYMR	63.62	6.0	-22.1	-3.48
2025-11-14	KYMR	64.86	6.0	-28.4	-3.48
2025-11-17	KYMR	64.05	6.0	-16.8	-3.48
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	KYMR	6.29	7.52	13.69
2025-10-21	KYMR	6.29	7.52	13.69
2025-10-22	KYMR	6.29	7.52	13.69
2025-10-23	KYMR	6.29	7.52	13.69
2025-10-24	KYMR	6.29	7.52	13.69
2025-10-27	KYMR	6.29	7.98	13.74
2025-10-28	KYMR	6.29	7.98	13.74
2025-10-29	KYMR	6.29	7.98	13.74
2025-10-30	KYMR	6.02	7.98	13.74
2025-10-31	KYMR	6.02	7.98	13.74
2025-11-03	KYMR	6.02	7.30	13.74
2025-11-04	KYMR	6.02	7.30	13.74
2025-11-05	KYMR	6.04	7.30	13.74
2025-11-06	KYMR	6.02	7.30	13.74
2025-11-07	KYMR	5.98	7.30	13.66
2025-11-10	KYMR	5.98	7.17	13.66
2025-11-11	KYMR	5.98	7.17	13.66
2025-11-12	KYMR	5.98	7.17	13.54
2025-11-13	KYMR	5.98	7.17	13.54
2025-11-14	KYMR	5.98	7.17	13.52
2025-11-17	KYMR	6.00	6.28	13.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.94

Avg. EPS Est. Current Quarter

-0.84

Avg. EPS Est. Next Quarter

-1

Insider Transactions

Institutional Transactions

6.28

Beta

2.28

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

30.3

Max Drawdown 5-Year %

-87.5

Target Price

76.14

P/E

Forward P/E

PEG

P/S

105.46

P/B

4.86

P/Free Cash Flow

EPS

-3.6

Average EPS Est. Cur. Y

-3.48

EPS Next Y. (Est.)

-3.87

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-674.81

Relative Volume

0.55

Return on Equity vs Sector %

-58.1

Return on Equity vs Industry %

-43.2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

-16.8

Kymera Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 225

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today

news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance

stock history KYMR – Kymera Therapeutics, Inc. invest stock market

stock prices KYMR premarket after hours

ticker KYMR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KYMR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y